Additional Information
Market: TSX
Sector: Medical
EPIC: VRX
Latest Price: 127.38  (0.62% Ascending)
52-week High: 164.96
52-week Low: 102.61
Market Cap: 42,724.70M
1 year chart
1 day chart
Valeant Pharmaceuticals
www.valeant.com

Valeant Pharmaceuticals International Inc., formerly Biovail Corporation, is a Canadian specialty pharmaceutical company engaged in the application of drug-delivery technologies to improve the clinical effectiveness of medicines. Its therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease (including Type II diabetes).

Valeant to buy dental company OraPharma for $312 mln

15th Jun 2012, 9:10 am by Brad Lemaire
Valeant to buy dental company OraPharma for $312 mln

Valeant Pharmaceuticals International (NYSE:VRX)(TSE:VRX) agreed to buy specialty oral health company OraPharma from Water Street Healthcare Partners in a deal valued at $312 million.

The deal, which is slated to close by June, also includes a payment of up to $114 million based on certain milestone and revenue targets.

The Mississauga, Ontario-based company, which recently announced its decision to move headquarters to Montreal, expects the transaction to be accretive this year.

"We are excited to enter a new attractive market segment with an already established sales infrastructure focused entirely on the dental community," Valeant’s chief executive Michael Pearson said in a statement. 

OraPharma's lead product is Arestin, a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system and is indicated for use in conjunction with scaling and root planing for the treatment of adult periodontitis.

Periodontitis is inflammation and infection of the ligaments and bones that support the teeth.

OraPharma currently has the largest specialized pharmaceutical salesforce in the dental industry. As of March 31, OraPharma’s 12-month net revenue reached $95 million.

"We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese."

Valeant’s share price closed at $45.95 Thursday on the New York Stock Exchange.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here